


CLAIMS

1. A compound of formula I:

5



FORMULA I

10 wherein substituents R1 - R7 and X are defined as follows:

R1, R2, R3 and R4 each independently are selected from hydrogen, halogen (selected from F, Cl, Br or I), a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen
15 (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as trifluoromethyl, C₁₋₆alkyloxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, carboxyl, cyano, nitro, formyl, hydroxy, and CO-R, COO-R, CONH-R, SO₂-R, and SO₂NH-R wherein R is a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with at least
20 one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality.

R5 is one of the following:

- (i) hydrogen, or
25 (ii) a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from

F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, or

(iii) CO-R8 or COOR8 or CONHR8 or SO2R8 wherein R8 may be

- a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, or
- an aryl group such as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as halogen (selected from F, Cl, Br or I), alkyl groups containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as trifluoromethyl, C₁₋₆alkyloxy, carboxyl, cyano, nitro, formyl, hydroxy, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, and amino, the latter nitrogen substituents optionally in the form of a pendant basic nitrogen functionality; as well as CO-R, COO-R, CONH-R, SO₂-R, and SO₂NH-R wherein R is a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, or
- a heteroaryl group such as a pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, indolyl, benzimidazole, quinolinyl group, which may additionally bear any combination, at any one ring position, of one or more substituents such as halogen (selected from F, Cl, Br or I), alkyl groups containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality; as well as trifluoromethyl, C₁₋₆alkyloxy, carboxyl, cyano, nitro, formyl, hydroxy, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality; as well as CO-R, COO-R, CONH-R, SO₂-R, and SO₂NH-R wherein R

is a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality.

5

R6 and R7 each independently are selected from:

- i) hydrogen, a halogen (selected from F, Cl, Br or I), or
- ii) an alkyl¹ group defined as a linear, branched or cycloalkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more heteroatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen (the latter optionally in the form of a pendant basic nitrogen functionality); as well as trifluoromethyl, carboxyl, cyano, nitro, formyl; as well as CO-R, COO-R, CONH-R, SO₂-R, and SO₂NH-R wherein R is a linear or branched alkyl group containing 1 to 10 carbon atoms and optionally substituted with at least one heteroatom, notably a halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality ; as well as a cycloalkyl or aryl or heteroaryl group optionally substituted by a pendant basic nitrogen functionality, or
- (iii) an aryl¹ group defined as phenyl or a substituted variant thereof bearing any combination, at any one ring position, of one or more substituents such as
 - halogen (selected from I, F, Cl or Br);
 - an alkyl¹ group;
 - a cycloalkyl, aryl or heteroaryl group optionally substituted by a pendant basic nitrogen functionality;
 - trifluoromethyl, O-alkyl¹, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl¹, N(alkyl¹)(alkyl¹), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality;
 - NHCO-R or NHCOO-R or NHCONH-R or NHSO₂-R or NHSO₂NH-R or CO-R or COO-R or CONH-R or SO₂-R or SO₂NH-R wherein R corresponds to hydrogen, alkyl¹, aryl or heteroaryl, or

20

25

(iv) a **heteroaryl¹** group defined as a pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, indolyl, benzimidazole, quinolinyl group, which may additionally bear any combination, at any one ring position, of one or more substituents such as

- 5 - halogen (selected from F, Cl, Br or I);
- an alkyl¹ group;
- a cycloalkyl, aryl or heteroaryl group optionally substituted by a pendant basic nitrogen functionality,
- trifluoromethyl, O-alkyl¹, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl¹, N(alkyl¹)(alkyl¹), and amino, the latter nitrogen substituents
- 10 optionally in the form of a basic nitrogen functionality;
- NHCO-R or NHCOO-R or NHCONH-R or NHSO₂-R or NHSO₂NH-R or CO-R or COO-R or CONH-R or SO₂-R or SO₂NH-R wherein R corresponds to hydrogen, alkyl¹, or
- 15 (v) an O-aryl¹, or NH-aryl¹, or O-heteroaryl¹ or NH-heteroaryl¹ group
- (vi) trifluoromethyl, O-alkyl¹, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl¹, N(alkyl¹)(alkyl¹), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality, or
- (vi) NHCO-R or NHCOO-R or NHCONH-R or NHSO₂-R or NHSO₂NH-R or CO-R
- 20 or COO-R or CONH-R or SO₂-R or SO₂NH-R wherein R corresponds to hydrogen, alkyl¹, aryl or heteroaryl.


X is:

- NR₉R₁₀, wherein R₉ and / or R₁₀ are hydrogen or:
- 25 i) an alkyl¹ group, CF₃ or
- ii) an aryl¹, heteroaryl¹ or cycloalkyl group optionally substituted by a pendant basic nitrogen functionality, or
- iii) a CO-R, COO-R, CON-RR' or SO₂-R, where R and R' are a hydrogen, alkyl¹, aryl¹ or heteroaryl¹, optionally substituted by a pendant basic nitrogen functionality;
- 30 or:
- CO-NR₉R₁₀, wherein R₉ and / or R₁₀ are hydrogen or:

- i) an alkyl¹ group, CF₃ or
 ii) an aryl¹, heteroaryl¹ or cycloalkyl group optionally substituted by a pendant basic nitrogen functionality.
 - alkyl¹

5

2. A compound according to claim 1 of formula I-2:




10

wherein R₅ = H, Y and Z represents an hydrogen, an aryl¹ or a heteroaryl¹ group, optionally substituted by a pendant basic nitrogen functionality and wherein R₁, R₂, R₃, R₄, R₆, and R₇ have the meaning as defined in claim 1.

15

3. A compound according to claim 1 of formula II:




FORMULA II

20

Wherein Y is selected from O, S and Z corresponds to H, NR_aR_b, alkyl¹, aryl¹, O-alkyl¹, or O-aryl¹ wherein R_a and R_b are independently chosen from H or alkyl¹ or aryl¹ or heteroaryl¹, optionally substituted by a pendant basic nitrogen functionality and wherein R₁, R₂, R₃, R₄, R₅, R₆, and R₇ have the meaning as defined in claim 1.

4. A compound according to claim 3 of formula II-1:




5

FORMULA II-1

Wherein R₅ = H, Y = O or S and Ra, Rb are independently chosen from H or alkyl¹ or aryl¹ or heteroaryl¹, optionally substituted by a pendant basic nitrogen functionality and wherein R₁, R₂, R₃, R₄, R₆, and R₇ have the meaning as defined in claim 1.

10

5. A compound according to claim 4 of formula II-2:




15

FORMULA II-2

Wherein A is aryl¹ or heteroaryl¹ and wherein R₁, R₂, R₃, R₄, R₆, R₇, aryl¹, heteroaryl¹ have the meaning described on pages as defined in claim 1.


20

6. A compound according to claim 4 of formula II-3:

**FORMULA II-3**

- 5 Wherein R is independently alkyl¹, aryl¹ or heteroaryl¹ and wherein R1, R2, R3, R4, R5, R6, and R7 have the meaning described as defined in claim 1.


7. A compound according to claim 4 of formula II-4:

**FORMULA II-4**

Wherein R1, R2, R3, R4, R6, R7 and alkyl¹ have the meaning as defined in claim 1.

15


8. A compound according to claim 1 of formula I-3:



FORMULA I-3


Wherein R5 = H, X is NHSO2R group, R is independently alkyl¹, aryl¹ or heteroaryl¹
and wherein alkyl¹, aryl¹, heteroaryl¹, R1, R2, R3, R4, R6 and R7 have the meaning
as defined in claim 1.

9. A compound according to claim 1 of formula III:

**FORMULA III**

Wherein Y is selected from NRaRb, NHNRaRb, alkyl¹, aryl¹, Ra wherein Ra and Rb
are independently chosen from H or alkyl¹ or aryl¹ or heteroaryl¹, optionally
substituted by a pendant basic nitrogen functionality and wherein R1, R2, R3, R4, R6,
and R7 have the meaning as defined in claim 1.

10. A compound according to claim 1 of formula IV:

**FORMULA IV**

Wherein alkyl¹, R1, R2, R3, R4, R6, and R7 have the meaning as defined in claim 1.

11. A compound as claimed in claim 1 selected from:

- 5 •4- {[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoic acid methyl ester;
- 4-Methyl-N1-(5-pyridin-3-yl-oxazol-2-yl)-N3-(5-pyridin-4-yl-oxazol-2-yl)-benzene-1,3-diamine;
- 4-Methyl-N1-(5-phenyl-oxazol-2-yl)-N3-(5-pyridin-4-yl-oxazol-2-yl)-benzene-1,3-diamine;
- 10 •4-Methyl-N1-(5-phenyl-[1,3,4]oxadiazol-2-yl)-N3-(5-pyridin-4-yl-oxazol-2-yl)-benzene-1,3-diamine;
- N1-Benzooxazol-2-yl-4-methyl-N3-(5-pyridin-4-yl-oxazol-2-yl)-benzene-1,3-diamine;
- 15 •N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- 2-Cyano-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- 2-Ethoxy-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- 3-Methoxy-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-propionamide;
- 1-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-*p*-tolyl-urea;
- 20 •1-(4-Cyano-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea;
- 1-(4-Fluoro-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea;
- 1-(2-Fluoro-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea;
- 1-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-(4-trifluoromethyl-phenyl)-urea;
- 25 •1-(4-Chloro-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-urea;
- 1-[4-Methyl-3-(5-phenyl-oxazol-2-ylamino)-phenyl]-3-(3-trifluoromethyl-phenyl)-urea;
- 1-(4-Cyano-phenyl)-3-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-thiourea;

- 1-(4-Cyano-phenyl)-3-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-thiourea;
- (2-{2-Methyl-5-[3-(4-trifluoromethyl-phenyl)-ureido]-phenylamino}-oxazol-5-yl)-acetic acid ethyl ester;
- 5 • 1-Benzyl-3-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-thiourea;
- 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- 3-Dimethylamino-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- 10 • 3-Bromo-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- N-[4-Methoxy-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 4-(3-Dimethylamino-propylamino)-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 15 • N-[4-Fluoro-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 1*H*-Indole-6-carboxylic acid [4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-amide;
- 3-Isopropoxy-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- 20 • N-[4-Methyl-3-(5-pyridin-2-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 3,5-Dimethoxy-N-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- N-[3-(5-Pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 25 • N-[4-Methyl-3-(5-phenyl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 3-Fluoro-4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- N-[4-Chloro-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- 30 • N-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-terephthalamide;

- 5-Methyl-isoxazole-4-carboxylic acid [4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-amide;
- 4-Cyano-*N*-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-benzamide;
- *N*-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-isonicotinamide;
- 5 • *N*-[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide;
- [4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-carbamic acid isobutyl ester;
- (5-Isobutoxycarbonylamino-2-methyl-phenyl)-(5-pyridin-3-yl-oxazol-2-yl)-carbamic acid isobutyl ester;
- 10 • [4-Methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-carbamic acid isobutyl ester;
- *N*-[4-Methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-2-*m*-tolyl-acetamide;
- 2-(4-Fluoro-phenyl)-*N*-[4-methoxy-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- 2-(2,4-Difluoro-phenyl)-*N*-[4-methyl-3-(5-phenyl-oxazol-2-ylamino)-phenyl]-acetamide;
- 15 • 2-(3-Bromo-phenyl)-*N*-[4-methyl-3-(5-pyridin-2-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- 3-(4-Fluoro-phenyl)-*N*-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-propionamide;
- 20 • 2-(4-Fluoro-phenyl)-*N*-[4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- *N*-{3-[5-(4-Cyano-phenyl)-oxazol-2-ylamino]-4-methyl-phenyl}-2-(2,4-difluoro-phenyl)-acetamide;
- 4-Methyl-pentanoic acid [4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-amide;
- 25 • *N*-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-2-piperazin-1-yl-acetamide;
- *N*-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-piperazin-1-yl-propionamide;

- 2-(2,6-Dichloro-phenyl)-*N*-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- N*-[4-Methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-phenyl]-3-pyrrolidin-1-yl-propionamide;
- 5 •*N*-[4-Methoxy-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-2-(4-trifluoromethyl-phenyl)-acetamide;
- 2-(4-Methoxy-phenyl)-*N*-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-acetamide;
- N*-[4-Methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-*C*-phenyl-methanesulfon-
10 amide;
- N*-(4-Cyano-phenyl)-4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-benzamide;
- N*-(3-Dimethylamino-phenyl)-4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-benzamide;
- N*-(2-Dimethylamino-ethyl)-4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-
15 benzamide;
- N*-(3-Fluoro-4-methyl-phenyl)-4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-benzamide;
- N*-(3-Chloro-phenyl)-4-methyl-3-(5-pyridin-3-yl-oxazol-2-ylamino)-benzamide;
- N*-Benzyl-4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-benzamide;
- 20 •*N*-(4-Methoxy-benzyl)-4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-benzamide;
- [4-Methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-morpholin-4-yl-methanone;
- [4-Methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-piperazin-1-yl-methanone;
- N*-(4-Fluoro-phenyl)-2-[4-methyl-3-(5-pyridin-4-yl-oxazol-2-ylamino)-phenyl]-
25 acetamide

12. A compound according to one of claims 1 to 10, wherein R6 is hydrogen and R7 is pyridyl, which may additionally bear any combination, at any one ring position, of one or more substituents such as

- 30 - halogen (selected from F, Cl, Br or I);
- an alkyl¹ group;
- an aryl¹ group;

- trifluoromethyl, O-alkyl¹, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl¹, N(alkyl¹)(alkyl¹), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality;
 - NHCO-R or NHCOO-R or NHCONH-R or NHSO₂-R or NHSO₂NH-R or CO-R or COO-R or CONH-R or SO₂-R or SO₂NH-R wherein R corresponds to hydrogen, alkyl¹ or aryl¹ group.
13. A pharmaceutical composition comprising a compound according to one of claims 1 to 12.
14. A pharmaceutical composition according to claim 13 further comprising a pharmaceutically acceptable carrier.
15. A pharmaceutical composition according to claim 14 formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, and suspensions.
16. A cosmetic or pharmaceutical composition for topical administration comprising a compound according to one of claims 1 to 12.
17. Use of a compound according to one of claims 1 to 12 to manufacture a medicament.
18. Use of a compound according to one of claims 1 to 12 to manufacture a medicament for treating neoplastic diseases such as mastocytosis, canine mastocytoma, solid tumours, human gastrointestinal stromal tumor ("GIST"), small cell lung cancer, non-small cell lung cancer, acute myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, myeloma 414, colorectal carcinomas, gastric carcinomas, badder gastrointestinal stromal tumors, testicular cancers, glioblastomas, astrocytomas, bladder cancer and cancer in the airway tracts.

19. Use of a compound according to one of claims 1 to 12 to manufacture a medicament for treating allergic diseases such as asthma, allergic rhinitis, allergic sinusitis, anaphylactic syndrome, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, erythema nodosum, erythema multiforme, cutaneous necrotizing
5 venulitis and insect bite skin inflammation and blood sucking parasitic infestation.
20. Use of a compound according to one of claims 1 to 12 to manufacture a medicament for treating inflammatory diseases such as rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic
10 conditions.
21. Use of a compound according to one of claims 1 to 12 to manufacture a medicament for treating autoimmune diseases such as multiple sclerosis, psoriasis, intestine inflammatory disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis
15 and polyarthritis, local and systemic scleroderma, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, dermatomyositis, polymyositis, Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy, as well as proliferative glomerulonephritis.
22. Use of a compound according to one of claims 1 to 12 to manufacture a medicament for treating graft-versus-host disease or graft rejection in any organ transplantation including kidney, pancreas, liver, heart, lung, and bone marrow.